Discussion and Review of Recent Literature In the case of our patient, it appears that she developed IIH due to the abrupt cessation of the GLP-1 receptor agonist prescribed to her with resultant rapid weight gain, with her BMI increasing from 29 to 34 in a little over a month
While neither medication is FDA-approved for combined use, some healthcare providers may consider this pairing in select cases
For evidence-based weight management, NICE guidelines recommend approaches focusing on dietary changes, physical activity, and behavioural support
They found other small peptides that control insulin and appetite by acting on two or even three metabolic switches instead of just one
Our experts will closely monitor your progress and address any concerns that arise.
Injectable GLP-1 receptor agonists provide predictable absorption of the active drug directly into systemic circulation, resulting in consistent glucose-lowering activity